|
Title
|
Publication Date
|
Price
|
Relevance
|
|
Antigenics Inc-Therapeutic Competitors
|
Mar 2011 |
£220 |
100% |
|
Antigenics, Inc. - Financial and Strategic Analysis Review
|
Jun 2009 |
£79 |
99% |
|
Antigen Express, Inc.-Deals & Alliances Report
|
Mar 2011 |
£380 |
98% |
|
Cancer Cell Therapy Markets
|
Mar 2008 |
£2,150 |
88% |
Cancer Vaccines
Market Forecasts, New Developments and Pipeline Analysis
|
Nov 2008 |
£2,525 |
84% |
|
Immunotherapy of Cancer
|
Jan 2007 |
£2,760 |
83% |
Innovations and Opportunities in Therapeutic Vaccines
Technology platforms, key players, and early pipeline candidates
|
Jul 2010 |
£2,425 |
82% |
Prostate Cancer: Vaccines and Therapeutic Antibodies
2011
|
Feb 2011 |
£1,490 |
81% |
Emerging Cancer Vaccines: Forecasts, Developments and Pipeline Analysis
4th Edition
|
Sep 2010 |
£2,525 |
79% |
|
Inverness Medical Innovations, Inc. Product Pipeline Analysis
|
Jan 2009 |
£475 |
79% |
Melanoma - Pipeline Review
Q1 2011
|
Feb 2011 |
£315 |
79% |
Renal Cell Carcinoma (RCC) Therapeutics
Pipeline Assessment and Market Forecasts to 2017
|
Dec 2010 |
£1,265 |
78% |
Metastatic Melanoma - Pipeline Review
H1 2012
|
Jan 2012 |
£325 |
78% |
|
Melanoma Therapeutics
|
Apr 2010 |
£2,500 |
77% |
Genital Herpes - Pipeline Review
H2 2011
|
Sep 2011 |
£315 |
76% |
|
Immunotherapies and Vaccines for Cancer and Infectious Diseases
|
Oct 2008 |
£2,370 |
71% |
|
Drug Delivery Technology: Developing a New Generation of Vaccines
|
Nov 2007 |
£945 |
68% |
Influenza - Pipeline Review
H2 2011
|
Sep 2011 |
£315 |
68% |
|
Cancer Diagnostic Testing World Markets
|
Jul 2011 |
£2,150 |
67% |
Herpes Simplex Infections - Pipeline Review
H2 2011
|
Sep 2011 |
£315 |
66% |
|
Herpes Simplex Virus Treatment
|
Apr 2011 |
£2,910 |
66% |
|
Labeling and Linkage Agents for Immunoassays and Gene Probes
|
Oct 2011 |
£3,065 |
66% |
H1N1 Infection (Swine Influenza) - Pipeline Review
H2 2011
|
Oct 2011 |
£315 |
66% |
Glioma - Pipeline Review
H1 2012
|
Jan 2012 |
£325 |
66% |
|
Molecular Diagnostics Markets
|
Jul 2011 |
£2,150 |
64% |
Non-Hodgkin Lymphoma - Pipeline Review
H2 2011
|
Sep 2011 |
£315 |
64% |
B-Cell Lymphomas - Pipeline Review
H1 2012
|
Jan 2012 |
£325 |
64% |
Non-Small Cell Lung Cancer - Pipeline Review
H2 2011
|
Sep 2011 |
£315 |
63% |
Prostate Cancer - Global Drug Forecasts and Treatment Analysis to 2020
Q4 2010
|
Nov 2010 |
£3,160 |
60% |
|
Anti-CD20 Monoclonal Antibodies
|
Jul 2010 |
£2,500 |
60% |
